A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02985957
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • Ipilimumab — BIOLOGICAL
    Specified dose on specified days
  • Cabazitaxel — DRUG
    Specified dose on specified days
  • Prednisone — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).

Key Dates

Start date
Mar 26, 2017
Status verified
Dec 2025
Primary completion
Apr 5, 2022
Completion
Jan 7, 2025

Study Design

Enrollment
351 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A (Arm A)
  • Experimental: Cohort B (Arm B)
  • Experimental: Cohort C (Arm C)
  • Experimental: Cohort D (Arm D1)
  • Experimental: Cohort D (Arm D2)
  • Experimental: Cohort D (Arm D3)
  • Experimental: Cohort D (Arm D4)

Primary Outcome Measure

Objective Response Rate (ORR) Cohorts B and C Per BICR [ Time Frame: From first dose to the date of objectively documented progression or the date of subsequent systemic anti-cancer therapy, whichever occurred first (assessed up to approximately 61 months) ]

Locations (15)

FacilityCityStateZIPSite coordinators
Local Institution - 0074TucsonArizona85711-
Local Institution - 0046MariettaGeorgia30060-
Local Institution - 0011ChicagoIllinois60637-
Local Institution - 0076MinneapolisMinnesota55404-
Local Institution - 0008St LouisMissouri63110-
Local Institution - 0075Las VegasNevada89169-
Local Institution - 0078AlbanyNew York12208-
Local Institution - 0065Lake SuccessNew York11042-
Local Institution - 0001New YorkNew York10029-
Local Institution - 0077TigardOregon97223-
Local Institution - 0047AllentownPennsylvania18105-
Local Institution - 0010PhiladelphiaPennsylvania19104-
Local Institution - 0067CharlestonSouth Carolina29425-
Local Institution - 0079AustinTexas78731-
Local Institution - 0002HoustonTexas77030-

Find similar trials in Tucson, AZ

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Local Institution - 0074· Tucson, AZLocal Institution - 0046· Marietta, GALocal Institution - 0011· Chicago, ILLocal Institution - 0076· Minneapolis, MNLocal Institution - 0008· St Louis, MOLocal Institution - 0075· Las Vegas, NV

Related Studies